AI drug discovery
An AI ran a whole protein-design campaign on its own
In 64 hours, a model drove a dozen design tools, screened half a million candidates and handed back 17 binders. The design step is becoming something you point at a problem and leave running.

Efthymios Vogiatzis · · 2 min read
Anthropic published a research result this week where an AI model ran almost the whole protein-design campaign itself.
The goal was small proteins that bind scorpion-sting toxins, the starting point for a possible future antivenom. The model drove 12 existing design tools on its own, generated candidates, folded them against the target, and chose which ones to send to the lab.
The scale it worked at: 318,484 designs generated, 553,052 design-and-target pairs folded and screened. From that it picked 211 to make and test. 17 met the binding criteria. Start to finished list took about 64 hours and roughly 10,000 hours of graphics-processor time, with the model working on its own for the first 24.
The team is careful about what this is not. It's not an antivenom. Binding was measured only against lab-made versions of the toxins, not venom itself, and nothing was tested for whether it actually neutralizes a sting in cells or animals.
Here's the arc. Two years ago the Nobel in chemistry went to computational protein design, the idea that you can design a working protein on a computer. That was about the method existing. This is about the method running itself: an agent that plans the campaign, spends the compute, reads its own results and narrows more than 500,000 candidates to a shortlist a human can test. They open-sourced all 211 designs.
The design step is becoming something you can point at a problem and leave running.
Sources
- Anthropichttps://www.anthropic.com/research/claude-scorpion-toxin-binder-design
- Technical reporthttps://www-cdn.anthropic.com/31ac578806cffd8b3d92d8affe6edc4c04d502e1.pdf
- Open datasethttps://huggingface.co/datasets/Anthropic/scorpion-toxin-binder-design
- Interesting Engineeringhttps://interestingengineering.com/ai-robotics/claude-scorpion-toxin-protein-binders
- The Decoderhttps://the-decoder.com/claude-science-tackles-deadly-scorpion-stings-by-designing-protein-binders-from-scratch/

Efthymios Vogiatzis
Efthymios Vogiatzis is a pharmacist turned AI and data product leader, and the founder of VE1 Advisory in Vienna. He has led AI, data and analytics work across life sciences, biopharmaceuticals, insurance and industrial technology.
Start a conversationField notes by email.
A new essay about once a month on AI, data integrity and the people side of change.
Keep reading
21 October 2026 · Operations · 2 min read
The quiet half of biotech: scaling it next to a sugar mill
A Brevel and Wave Group plant jumps from a 5,000-litre tank to 300,000 litres, on a feedstock sitting next door. Scale-up is the half that decides whether biology reaches a shelf.
September 2026 · AI drug discovery · LinkedIn
What a pharmacist sees in the AI pipeline
The habits that keep data honest when the model moves faster than the audit trail.
